|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians显示文摘Pancreatic cancer(PC) would become the second leading cause of cancer death in the near future, despite representing only 3% of new cancer diagnosis. Survival improvement will come from a better knowledge of risk factors, earlier diagnosis, better integration of locoregional and systemic therapies, as well as the development of more efficacious drugs rising from a deeper understanding of disease biology. For patients with unresectable, non-metastatic disease, combined strategies encompassing primary chemotherapy and radiation seems to be promising. In fit patients, new polychemotherapy regimens can lead to better outcomes in terms of slight but significant survival improvement associated with a positive impact on quality of life. The upfront use of these regimes can also increase the rate of radical resections in borderline resectable and locally advanced PC. Second line treatments showed to positively affect both overall survival and quality of life in fit patients affected by metastatic disease. At present, oxaliplatin-based regimens are the most extensively studied. Nonetheless, other promising drugs are currently under evaluation. Presently, in addition to surgery and conventional radiation therapy, new locoregional treatment techniques are emerging as alternative options in the multimodal approach to patients or diseases not suitable for radical surgery. As of today, in contrast with other types of cancer, targeted therapies failed to show relevant activity either alone or in combination with chemotherapy and, thus, current clinical practice does not include them. Up to now, despite the fact of extremely promising results in different tumors, also immunotherapy is not in the actual therapeutic armamentarium for PC. In the present paper, we provide a comprehensive review of the current state of the art of clinical practice and research in PC aiming to offer a guide for clinicians on the most relevant topics in the management of this disease. | Rosella Spadi Federica Brusa Agostino Ponzetti Isabella Chiappino Nadia Birocco Libero Ciuffreda Maria Antonietta Satolli | 2016 | World Journal of Clinical Oncology2016，7，1： | 15 |
| 2 | Gastric cancer:The times they are a-changin'显示文摘Gastric cancer is the third leading cause of cancer death worldwide.Even though during these last decades gastric cancer incidence decreased in Western countries,it remains endemic and with a high incidence in Eastern countries.The survival in advanced and metastatic stage of gastric cancer is still very poor.Recently the Cancer Genoma Atlas Research Network identified four subtypes with different molecular profiles to classify gastric cancer in order to offer the optimal targeted therapies for pre-selected patients.Indeed,the key point is still the selection of patients for the right treatment,on basis of molecular tumor characterization.Since chemotherapy reached a plateau of efficacy for gastric cancer,the combination between cytotoxic therapy and biological agents gets a better prognosis and decreases chemotherapeutic toxicity.Currently,Trastuzumab in combination with platinum and fluorouracil is the only approved targeted therapy in the first line for c-erb B2 positive patients,whereas Ramucirumab is the only approved targeted agent for patients with metastatic gastric cancer.New perspectives for an effective treatment derived from the immunotherapeutic strategies.Here,we report an overview on gastric cancer treatments,with particular attention to recent advances in targeted therapies and in immunotherapeutic approach. | Maria Antonietta Satolli Lucio Buffoni Rosella Spadi Ilaria Roato | 2015 | World Journal of Gastrointestinal Oncology2015，7，11： | 6 |
| 3 | Synthesis and characterization of Li2MxMn4-xO8 (M=Co, Fe) as positive active materials for lithium-ion cells 显示文摘 | BONINO F PANERO S SATOLLI D SCROSATI B | 2001 | Journal of Power Sources2001，9798，： | 1 |
| 4 | Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer显示文摘 | Sofia Asioli Francesca Maletta Ludovica Verdun di Cantogno Maria A. Satolli Marina Schena Carla Pecchioni Cristina Botta Luigi Chiusa Luca Molinaro Luca Conti Giuseppe Viale Giuseppe Ingravallo Eugenio Maiorano Anna Sapino | 2012 | Human Pathology2012，，11： | 1 |
| 5 | 《临床证据》入选意大利国家继续医学教育项目显示文摘尽管循证医学(EBM)对卫生政策和临床实践的影响尚未确定,但在意大利,人们对循证医学的兴趣却与日俱增。意大利医生的信息需求很大程度上仍依赖于药厂,而非无偏倚的循证资源。例如,近期一项调查显示:全科医生每周会接受11次医药代表的来访。该调查表明医生认为药厂提供的信息完整且可靠性较高。 | Lorenzo Moja Ivan Moschetti Alessandro Liberati Roberto Manfrini Christian Deligant Roberto Satolli Antonio Addis Nello Martini Pietro Dri 陈耀龙(译) 刁骧(审校) | 2007 | 中国循证医学杂志2007，7，5： | 1 |
| 6 | Advanced non-small cell lung cancer in elderly patients: A review显示文摘Over 50% of patients diagnosed with non-smallcell lung cancer(NSCLC) are 65 years old while 30% exceed 70 years old. Comparing elderly patients to their younger counterpart they poorly tolerate chemotherapy due to progressive reduction of organ function and age-related co-existing pathologies. Due to this reason elderly are usually excluded from platinum-based chemotherapy, which still represent the standard of care for advanced NSCLC. In every-day practice, single-agent schedule with a third-generation drug is the recommended option for elderly patients with advanced NSCLC. A modest increase in toxicity for elderly patients has been demonstrated by subgroup analyses concluding for platinum-based combination chemotherapy being similar in young patients and fit elderly. Even though the cited evidence, feasibility of chemotherapy based on platinum remains an open question. Prospective randomised trials are warranted in order to change guide lines and give the clinicians a new therapeutic option. Recent emerging role of molecular target in selecting patients for new targeted therapies suggest dedicated trials for elderly patients. The same is for more accurate evaluation of elderly patients with increasing evidence for a comprehensive geriatric assessment as a valid tool for customized treatment in NSCLC elderly patients. Suitable evidences for the treatment of elderly patients affected by advanced NSCLC together with more appropriate and validated tools for patients selection are reviewed along the manuscript. | Lucio Buffoni Lorena Consito Andrea Riccardo Filippi Enrico Ruffini Paolo Solidoro Paolo Bironzo Maria Antonietta Satolli Marina Schena Libero Ciuffreda | 2015 | World Journal of Respirology2015，5，2： | 1 |
| 7 | Magneticstratigraphy of Kimmeridgian-Aptian sections from Umbria-March (Italy): New details on the M polarity sequence显示文摘 | SPERANZA F SATOLLI S MATTIOLI 2005 | 2005 | Journal of Geophysical Research2005，110，12： | 1 |
| 8 | The role of angiogenesis in renal carcinoma显示文摘 | Bussolati B Satolli MA Camussi G | 2008 | G hal Nefrol2008，25，3： | 1 |
| 9 | High volt- age lithium polymer ceils using a PAN - based composite electrolyte 显示文摘 | Panero S Satolli D D Epifano A Scrosati B | 2002 | Electrochem Soc2002，149，： | 1 |
| 10 | Synthesis and characterization of Li2MxMn4-xO8 (M=Co, Fe) as positive active materials for lithium-ion cells 显示文摘 | BONINO F PANERO S SATOLLI D SCROSATI B | 2001 | Journal of Power Sources2001，9798，： | 1 |
| 11 | Synthesis and characterization of Li2MxMn4-xO8 (M=Co,Fe) as positive active materials for lithium-ion cells显示文摘 | BONINO F PANERO S SATOLLI D SCROSATI B | 2001 | J Power Sources2001，9798，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员